Review
Open access
An antisense antidote to oncogenic poison exons
Medicine
TL;DR
A study in this issue of Genes & Development by Islam et al. that identifies and targets a poison exon inclusion event that controls EZH2 expression in SRSF2 mutated cancer is discussed.
Abstract
In this Outlook, Arvola and Singh discuss a study in this issue of Genes & Development by Islam et al. that identifies and targets a poison exon inclusion event that controls EZH2 expression in SRSF2 mutated cancer. The authors highlight recent advances in targeting such poison exons with antisense oligonucleotides for new cancer therapeutics.